HeraMED (ASX:HMD) has raised US$2.8 million via placement and SPP
June 2020 — HeraMED Limited (ASX:HMD) has raised funds to accelerate HearCARE’s commercial roll out and progress ongoing research projects.
HeraMED is a medical technology company leading the digital transformation of maternity care with its proprietary telehealth platform. The company offers a platform that utilizes hardware and software to reshape the doctor/patient relationship using its clinically validated in-home fetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.
Our role in the transaction
Oaklins’ team in Australia acted as lead manager in this transaction.
Talk to the deal team
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn more